Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06790303 · ClinicalTrials.gov registry record · Phase 2
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT06790303 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 8 participants.
The verdict
NCT06790303, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess the clinical activity of novel regimen (Feladilimab plus Ipilimumab) in participants with NSCLC.
Interventions
- DRUG Ipilimumab
- DRUG Feladilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2021-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06790303
The ClinicalTrials.gov registry entry for NCT06790303 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT06790303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06790303 about?
NCT06790303 is a clinical study titled "Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2". This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess the clinical activity of novel regimen (Feladilimab plus Ipilimumab) in participants with NSCLC.
What is the current status of trial NCT06790303?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2021-03-04. Estimated completion is 2021-09-23.
What interventions are being tested in trial NCT06790303?
The interventions under investigation include: Ipilimumab (DRUG), Feladilimab (DRUG).
Who is sponsoring clinical trial NCT06790303?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.